 ABINGDON, OXFORDSHIRE ACCESSWIRE January 8, 2020 Midatech Pharma PLC AIM: MTPH.L; Nasdaq: MTP, an RD; biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce positive headline results from Study 102. The study met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration. The results demonstrate that MTD201 can deliver sustained plasma octreotide concentrations within the range needed for therapeutic efficacy with an injection interval of six to eight weeks by either subcutaneous or intramuscular administration. 